The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
CONCLUSION: The results showed that the odds of reporting an AEFI after COVID-19 vaccination is significantly higher in the presence of some comorbidities whilst flare-ups are uncommon after receiving COVID-19 vaccination in people with rheumatic disease. In-depth research is needed to validate our results and unravel the observed associations from a mechanistic perspective.PMID:37796980 | DOI:10.1080/14740338.2023.2267971 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: C Ouaddouh J W Duijster T Lieber F P A M van Hunsel Source Type: research
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS
CONCLUSIONS: The analysis of the AE signals may provide support for prescribing flutamide and bicalutamide.PMID:37795911 | DOI:10.1080/14740338.2023.2267978 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: Yu Sun Tao Xu Suyan Zhu Hongbin Xu Source Type: research
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
CONCLUSION: The results showed that the odds of reporting an AEFI after COVID-19 vaccination is significantly higher in the presence of some comorbidities whilst flare-ups are uncommon after receiving COVID-19 vaccination in people with rheumatic disease. In-depth research is needed to validate our results and unravel the observed associations from a mechanistic perspective.PMID:37796980 | DOI:10.1080/14740338.2023.2267971 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: C Ouaddouh J W Duijster T Lieber F P A M van Hunsel Source Type: research
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS
CONCLUSIONS: The analysis of the AE signals may provide support for prescribing flutamide and bicalutamide.PMID:37795911 | DOI:10.1080/14740338.2023.2267978 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: Yu Sun Tao Xu Suyan Zhu Hongbin Xu Source Type: research
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
CONCLUSION: The results showed that the odds of reporting an AEFI after COVID-19 vaccination is significantly higher in the presence of some comorbidities whilst flare-ups are uncommon after receiving COVID-19 vaccination in people with rheumatic disease. In-depth research is needed to validate our results and unravel the observed associations from a mechanistic perspective.PMID:37796980 | DOI:10.1080/14740338.2023.2267971 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: C Ouaddouh J W Duijster T Lieber F P A M van Hunsel Source Type: research
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS
CONCLUSIONS: The analysis of the AE signals may provide support for prescribing flutamide and bicalutamide.PMID:37795911 | DOI:10.1080/14740338.2023.2267978 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: Yu Sun Tao Xu Suyan Zhu Hongbin Xu Source Type: research
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
CONCLUSION: The results showed that the odds of reporting an AEFI after COVID-19 vaccination is significantly higher in the presence of some comorbidities whilst flare-ups are uncommon after receiving COVID-19 vaccination in people with rheumatic disease. In-depth research is needed to validate our results and unravel the observed associations from a mechanistic perspective.PMID:37796980 | DOI:10.1080/14740338.2023.2267971 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: C Ouaddouh J W Duijster T Lieber F P A M van Hunsel Source Type: research
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS
CONCLUSIONS: The analysis of the AE signals may provide support for prescribing flutamide and bicalutamide.PMID:37795911 | DOI:10.1080/14740338.2023.2267978 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: Yu Sun Tao Xu Suyan Zhu Hongbin Xu Source Type: research
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
CONCLUSION: The results showed that the odds of reporting an AEFI after COVID-19 vaccination is significantly higher in the presence of some comorbidities whilst flare-ups are uncommon after receiving COVID-19 vaccination in people with rheumatic disease. In-depth research is needed to validate our results and unravel the observed associations from a mechanistic perspective.PMID:37796980 | DOI:10.1080/14740338.2023.2267971 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: C Ouaddouh J W Duijster T Lieber F P A M van Hunsel Source Type: research
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS
CONCLUSIONS: The analysis of the AE signals may provide support for prescribing flutamide and bicalutamide.PMID:37795911 | DOI:10.1080/14740338.2023.2267978 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: Yu Sun Tao Xu Suyan Zhu Hongbin Xu Source Type: research
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
CONCLUSION: The results showed that the odds of reporting an AEFI after COVID-19 vaccination is significantly higher in the presence of some comorbidities whilst flare-ups are uncommon after receiving COVID-19 vaccination in people with rheumatic disease. In-depth research is needed to validate our results and unravel the observed associations from a mechanistic perspective.PMID:37796980 | DOI:10.1080/14740338.2023.2267971 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: C Ouaddouh J W Duijster T Lieber F P A M van Hunsel Source Type: research
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS
CONCLUSIONS: The analysis of the AE signals may provide support for prescribing flutamide and bicalutamide.PMID:37795911 | DOI:10.1080/14740338.2023.2267978 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: Yu Sun Tao Xu Suyan Zhu Hongbin Xu Source Type: research
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
CONCLUSION: The results showed that the odds of reporting an AEFI after COVID-19 vaccination is significantly higher in the presence of some comorbidities whilst flare-ups are uncommon after receiving COVID-19 vaccination in people with rheumatic disease. In-depth research is needed to validate our results and unravel the observed associations from a mechanistic perspective.PMID:37796980 | DOI:10.1080/14740338.2023.2267971 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - October 5, 2023 Category: Drugs & Pharmacology Authors: C Ouaddouh J W Duijster T Lieber F P A M van Hunsel Source Type: research
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation
Expert Opin Drug Saf. 2023 Sep 28. doi: 10.1080/14740338.2023.2265295. Online ahead of print.ABSTRACTINTRODUCTION: Generalized pustular psoriasis (GPP) is a rare form of psoriasis (less of 1% of cases). Currently, GPP is recognized as a clinical entity, distinguished from plaque psoriasis. However, there are not guidelines for GPP management and treatments are often derived from plaque psoriasis. Therefore, conventional systemic drugs are usually used as first-line treatment options, and biologics are still used off label. Recently, spesolimab, an anti-IL36 receptor humanized IgG1 monoclonal antibody, has been specifically...
Source: Expert Opinion on Drug Safety - September 28, 2023 Category: Drugs & Pharmacology Authors: Luca Potestio Elisa Camela Sara Cacciapuoti Fabrizio Martora Luigi Guerriero Luigi Fornaro Angelo Ruggiero Matteo Megna Source Type: research
